When a Thyroid Hormone Masquerades as a Fertility Drug: Rare Case Explained

A 26-year-old woman arrived at an emergency department in Bogotá with severe abdominal pain, diarrhea, and a abdomen swollen with fluid. Her ovaries were massively enlarged and riddled with cysts, and her belly was filled with tense ascites. To any experienced clinician, the picture looked exactly like ovarian hyperstimulation syndrome, the potentially dangerous complication of fertility treatment in which the ovaries overreact to hormonal stimulation. Yet this young woman had never taken a single fertility drug. The explanation, reported in the Journal of Ovarian Research by a team from the Universidad Nacional de Colombia and two Bogotá health networks, was stranger and arguably more fascinating: her own thyroid-stimulating hormone, accumulating to critical levels after her thyroid had been removed, had been quietly impersonating the very hormone that fertility clinics inject on purpose.

The condition is called spontaneous ovarian hyperstimulation syndrome, or sOHSS, and it is exceptionally rare. Unlike the iatrogenic form that obstetricians and reproductive endocrinologists encounter during assisted reproduction, spontaneous OHSS arises without any exogenous ovulation induction. The authors classify the hypothyroidism-associated variety as Type III sOHSS, distinguishing it from cases linked to mutations in the follicle-stimulating hormone receptor or to pregnancy-derived hormonal triggers. In this patient, the underlying story began years earlier: she had undergone a total thyroidectomy for papillary thyroid carcinoma, the standard surgical treatment for this common and usually curable form of thyroid cancer. Total thyroidectomy removes the body’s only source of thyroid hormones, which means patients must take daily levothyroxine replacement for the rest of their lives, with dosing monitored through blood tests of thyroid-stimulating hormone.

That monitoring, evidently, had failed. When the woman reached the emergency department, laboratory evaluation revealed a critical elevation of thyroid-stimulating hormone, the pituitary signal that normally commands the thyroid gland to produce thyroxine. In a person without a thyroid, TSH rises when replacement doses are insufficient, and in profound primary hypothyroidism the levels can climb to extraordinary heights. Crucially, her follicle-stimulating hormone level was normal. FSH is the hormone that drives ovarian follicle development, so a normal FSH should have meant quiet, quiescent ovaries. Instead, imaging confirmed bilateral multicystic ovarian enlargement and massive ascites, the hallmark combination of hyperstimulation. Something other than FSH was activating her ovaries, and the prime suspect was the flood of TSH circulating in her blood.

The mechanism proposed by the authors is known as specificity spillover, a concept rooted in the structural biology of hormone receptors. TSH and FSH belong to the same family of glycoprotein hormones, along with luteinizing hormone and human chorionic gonadotropin, and they share a common alpha subunit while differing in their beta subunits. Their receptors, likewise, are evolutionarily related G-protein-coupled receptors with large extracellular domains that recognize their cognate hormones. That structural kinship comes at a price: at sufficiently high concentrations, one glycoprotein hormone can cross-activate the receptor of another. The FSH receptor is notoriously promiscuous in this regard, and the title of the paper invokes molecular mimicry to describe the phenomenon in which TSH, present at pathological concentrations, binds and stimulates FSH receptors on the ovarian granulosa cells. The result is follicular recruitment and cystic ovarian enlargement in the absence of any fertility treatment, driven entirely by a hormone that was never intended to act on the ovary.

This is not merely a biochemical curiosity; it is a clinical trap. Severe abdominal pain, ascites, and bilateral multicystic ovarian enlargement in a young woman can suggest a number of ominous possibilities, including ovarian tumors requiring surgical exploration. The authors emphasize that prompt recognition of severe hypothyroidism as a cause of spontaneous OHSS is vital to avoid unnecessary surgical interventions. Operating on ovaries that are merely responding to a reversible hormonal signal, in a patient whose real problem is a missing thyroid and inadequate hormone replacement, would expose her to surgical risk without addressing the underlying cause. The diagnostic key in this case was the laboratory panel: a critically elevated TSH alongside a normal FSH, a combination that redirects the entire differential diagnosis toward the pituitary-thyroid axis rather than the ovary itself.

The treatment, once the correct diagnosis was made, was elegantly simple. Management centered on levothyroxine replacement, restoring the thyroid hormone levels that the pituitary was so desperately demanding, combined with supportive care for the ascites and abdominal symptoms. As TSH levels were brought down, the spurious stimulation of the FSH receptors ceased, and the ovaries were allowed to return to their normal state. The authors report complete resolution of both symptoms and radiologic findings, with a satisfactory clinical evolution. No surgery was needed, no fertility was lost, and the entire dramatic presentation dissolved once the hormonal signal that had been misdirecting her ovaries was corrected. The case stands as a textbook demonstration that in endocrinology, removing the inciting signal can be more powerful than any intervention aimed at the target organ.

For clinicians, the case carries several practical lessons. First, patients who have undergone total thyroidectomy depend entirely on consistent replacement therapy and regular monitoring; lapses in either can produce profound hypothyroidism with consequences far beyond fatigue and weight gain. Second, spontaneous OHSS belongs on the differential diagnosis of cystic ovarian enlargement with ascites, particularly when the patient has a history of thyroid disease or thyroidectomy. Third, the laboratory pattern matters enormously: an elevated TSH with a normal FSH in a woman with multicystic ovaries should immediately raise the possibility of specificity spillover, sparing her from invasive workups. The authors also note the broader relevance to reproductive medicine, since understanding how and why glycoprotein hormones cross-react at high concentrations informs both the safety monitoring of fertility treatments and the interpretation of unusual ovarian presentations in endocrine patients.

The report also highlights the remarkable specificity of the human endocrine system, and the limits of that specificity. Receptors evolved to distinguish between hormones that differ by only a handful of amino acids in their beta subunits, and they do so with impressive fidelity at physiological concentrations. But biology is a matter of degrees, and when a hormone accumulates to levels orders of magnitude beyond anything evolution anticipated, the discriminating power of even a well-designed receptor can be overwhelmed. Specificity spillover has been described in other contexts, including FSH receptor activation by human chorionic gonadotropin in pregnancy-related spontaneous OHSS and by TSH in severe hypothyroidism, but documented cases remain scarce enough that each one contributes meaningfully to the medical literature. This report, published as an open-access article with a permanent DOI, adds a well-documented post-thyroidectomy example to a very short list.

Ethical oversight for the report was thorough: the protocol was approved by the institutional ethics committee of the Subred Integrada de Servicios de Salud Sur, the study complied with the Helsinki Declaration and Colombian research regulations, and the patient signed written informed consent in the presence of two witnesses, authorizing the anonymous use of her medical history and images for scientific publication. The authors declare no competing interests, and the research received no specific grant from any funding agency. The article was published on 29 August 2026 in the Journal of Ovarian Research, a Springer Nature journal, as a peer-reviewed case report from a Colombian team spanning the Universidad Nacional de Colombia and two public health networks in Bogotá.

Ultimately, the story of this young woman is a vivid reminder that the body’s hormones form an interconnected web in which one signal, when amplified beyond all normal bounds, can be mistaken for another with dramatic physical consequences. A missing thyroid gland, a lapse in replacement therapy, and a pituitary gland pushing TSH to desperate extremes were enough to transform a routine endocrine failure into an ovarian emergency that mimicked the complications of a fertility clinic. That the entire syndrome could be reversed with nothing more than the correct dose of a synthetic thyroid hormone is a testament to precise endocrine diagnosis, and a warning worth broadcasting: sometimes the most dangerous mimic in medicine is the patient’s own chemistry.

Subject of Research: TSH-induced spontaneous ovarian hyperstimulation syndrome via FSH receptor cross-activation in severe post-thyroidectomy hypothyroidism

Article Title: TSH-induced post thyroidectomy spontaneous ovarian hyperstimulation syndrome: a rare case report of molecular mimicry

Article References: Rojas-Oviedo, J. L., Leal Walteros, M. F., Mejía Pérez, D. L., Castellanos Corredor, J. E., Vargas Fiesco, D. C., Vallejo-Soto, J. C., & Marín Henao, V. (2026). TSH-induced post thyroidectomy spontaneous ovarian hyperstimulation syndrome: a rare case report of molecular mimicry. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02239-y

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02239-y

Keywords: ovarian hyperstimulation syndrome, spontaneous OHSS, thyroid-stimulating hormone, hypothyroidism, thyroidectomy, specificity spillover, FSH receptor, molecular mimicry, levothyroxine, ascites, multicystic ovaries, Journal of Ovarian Research